S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
S&P 500   4,769.83
DOW   37,689.54
QQQ   409.52
US Navy helicopters fire at Yemen's Houthi rebels and kill several in latest Red Sea shipping attack
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
A lithium-ion battery fire in a cargo ship's hold is out after several days of burning
Chief Justice Roberts casts a wary eye on the uses of artificial intelligence in the federal courts
New Year's Sale: Get MarketBeat All Access Free For 30 Days (Ad)
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$878.29
-3.41 (-0.39%)
(As of 12/29/2023 ET)
Today's Range
$875.62
$883.34
50-Day Range
$775.18
$881.70
52-Week Range
$668.00
$899.86
Volume
534,334 shs
Average Volume
610,387 shs
Market Capitalization
$95.69 billion
P/E Ratio
25.05
Dividend Yield
N/A
Price Target
$908.12

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
3.4% Upside
$908.12 Price Target
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.55mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$8.01 M Sold Last Quarter
Proj. Earnings Growth
5.65%
From $36.26 to $38.31 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

430th out of 950 stocks

Pharmaceutical Preparations Industry

202nd out of 442 stocks


REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
REGN Feb 2024 830.000 put
Claim Your $300 MarketBeat Account Credit
Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)
REGN Jan 2024 860.000 put
MarketBeat All Access New Year's Sale - Just $1.00
Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at StockNews.com
Regeneron Gains After Eye-Drug Patent Victory Over Viatris
REGN Dec 2023 852.500 put
REGN Dec 2025 940.000 call
REGN Jan 2026 800.000 put
14 Analysts Assess Regeneron Pharmaceuticals: What You Need To Know
RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/31/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/02/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
11,851
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$908.12
High Stock Price Target
$1,050.00
Low Stock Price Target
$680.00
Potential Upside/Downside
+3.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
26 Analysts

Profitability

Net Income
$4.34 billion
Pretax Margin
33.42%

Debt

Sales & Book Value

Annual Sales
$13.10 billion
Cash Flow
$44.54 per share
Book Value
$207.31 per share

Miscellaneous

Free Float
99,327,000
Market Cap
$95.69 billion
Optionable
Optionable
Beta
0.14

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

26 brokers have issued 1-year price targets for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,050.00. On average, they expect the company's stock price to reach $908.12 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 at the beginning of the year. Since then, REGN stock has increased by 21.7% and is now trading at $878.29.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 2nd 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported $10.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.39 by $0.78. The biopharmaceutical company earned $3.36 billion during the quarter, compared to analyst estimates of $3.23 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 18.61% and a net margin of 30.47%. The firm's revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $9.98 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 12/31/2023 by MarketBeat.com Staff

My Account -